Gapping up
In reaction to strong earnings/guidance:
- INFU +11.3%, VNET +7.2%, HDS +4.1%, GDS +3%, REN +2.1%, TTEC +2.1%, UAL +2.1%, (guidance) AMPH +2%, CLAR +1.4%, X +1%, (provides 2018 guidance with EBITDA of approx $1.7 bln and reaffirms Q1 EBITDA guidance of approx $250 mln), IRET +0.8%
M&A news:
- AVGO +1.4% (Qualcomm acquisition by Broadcom (AVGO) blocked by President Trump)
Other news:
- PTI +53.4% ( announces that the FDA has granted Breakthrough Therapy Designation for PTI-428, the Co's cystic fibrosis transmembrane conductance regulator (CFTR) amplifier)
- ALT +14.9% (Altimmune announces data from a pre-clinical study comparing SparVax-L and BioThrax against anthrax infection; data from the study showed a 67% survival rate in animals challenged with a lethal dose of anthrax after a single dose of SparVax-L)
- ATHX +10.9% (binding letter of intent to expand MultiStem collaboration)
- BLCM +9.6% (reports interim clinical data of BPX-501 in pediatric patients with acute myeloid leukemia and primary immunodeficiencies)
- AMRN +4.6% (Vascepa showed reductions in potentially atherogenic lipids and inflammatory markers )
- WTI +2.9% (W&T Offshore entered into joint exploration and development agreements with a group of investors with initial capital commitment of $230.5 million)
- INTC +2.2% (positive mention on MadMoney)
- DRYS +1.4% (modestly higher after releasing investor presentation)
- CERS +1% (announces that the Community Blood Center of Appleton, Wisconsin received approval by the FDA on the BLA requesting allowance of interstate distribution of platelets that have been pathogen-reduced with the INTERCEPT Blood System)
Analyst comments:
- MU +3.8% (target raised to $66 at Mizuho)